To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

NCT01478503 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetics
Healthy Subjects

Interventions

DRUG: mirabegron OCAS
DRUG: Placebo

Sponsor

Astellas Pharma Inc